SLSuzanne Lam

Suzanne Lam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Suzanne Lam has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Marc Dhenain

    Neuro-Bicêtre, Inserm U1195, CNRS EMR2000, Université Paris-Saclay, Bâtiment Gregory Pincus, Le Kremlin Bicêtre, France

    6 shared publications
  • Anne-Sophie Hérard

    Université Paris-Saclay, Commissariat à l’Énergie Atomique et aux Énergies Alternatives, Translational Research Approaches for Therapeutics, Modeling and Imaging of Neurodegenerative Diseases (TREATMIND) and Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France

    3 shared publications
  • Jean-Luc Picq

    Université Paris-Saclay, CEA, CNRS, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265 Fontenay-aux-Roses, France

    3 shared publications
  • Luc Buée

    Univ. Lille, Inserm, CHU-Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France

    3 shared publications
  • Charles Duyckaerts

    Laboratoire de Neuropathologie Escourolle, Hôpital de la Salpêtrière, Paris, France

    2 shared publications
  • Fanny Petit

    Université Paris-Saclay, CEA, CNRS, Laboratoire des Maladies Neurodégénératives, 18 Route du Panorama, F-92265 Fontenay-aux-Roses, France

    2 shared publications

Latest Publications

  • Transmission of Alzheimer pathology in murine and primate models : from proteinopathies to neuronal and cognitive impairments

    by Suzanne Lam

    Transmission de la pathologie Alzheimer à des modèles murins et primates : des protéinopathies aux altérations neuronales et cognitives: La maladie d’Alzheimer (MA) se caractérise par l’agrégation cérébrale de protéines β-amyloïde (Aβ) et tau mal conformées, ainsi que par des processus neuroinflammatoires et neurodégénératifs menant à des troubles cognitifs. Des études chez l’Homme et des modèles animaux suggèrent que les pathologies Aβ et tau sont transmissibles de manière similaire aux prions. L’impact neuronal et cognitif de cette transmission et les relations entre les marqueurs de la MA sont mal connus. Ce travail étudie la transmission de la pathologie Alzheimer dans des modèles murins et primates après inoculation cérébrale d’extraits cérébraux de patients MA.Premièrement, nous avons montré que l’inoculation de cerveau Alzheimer dans un modèle murin d’amyloïdose entraine des pathologies Aβ et tau, une microgliose et dans certains cas, des atteintes synaptiques et cognitives. La perte synaptique et les troubles cognitifs étaient associés à la pathologie tau, à une réduction de l’activité microgliale et, de manière plus modérée, aux lésions Aβ.Ensuite, nous avons montré pour la première fois chez un primate que l’inoculation de cerveau Alzheimer entraine des dépôts Aβ et tau chez le microcèbe (Microcebus murinus), ainsi que des troubles cognitifs et fonctionnels, une atrophie cérébrale et une perte neuronale.En conclusion, ces travaux montrent que les pathologies Aβ et tau, des pertes synaptiques/neuronales et des signes cliniques majeurs peuvent être expérimentalement transmis à des modèles murins et primates. Ces modèles offrent de nouvelles opportunités pour caractériser la MA et explorer de nouveaux biomarqueurs et thérapies. De plus, nos données expérimentales soulignent l’impact potentiel d’une transmission des pathologies Aβ et tau en matière de troubles cognitifs et d’atrophie cérébrale. L’évaluation systématique des biomarqueurs de la MA reflétant ces aspects de la pathologie chez des patients à risque de développer des lésions Aβ et tau d’origine iatrogène devient ainsi indispensable.

  • Open Access

    Normal aging increases white matter microglial reaction and perivascular macrophages in the microcebe primate

    by Léo Dupuis, Lolie Garcia, Fanny Petit, Suzanne Lam, Helene Eliane Hirbec, Jean-Luc Picq, Delphine Boche, Marc Dhenain

    As populations age, the incidence of neurodegenerative disorders is rising. Early age-related neuropathological changes are the breeding ground for the development of these disorders. Microglia are the resident macrophages of the central nervous system. They play crucial roles in maintaining brain homeostasis, yet their age-related changes remain not fully understood. While age-related microglia changes have been strongly characterized in rodents, studies in non-human primates are scarce. The microcebe primate (mouse lemur ( Microcebus murinus )) is widely used as a model for cerebral aging and to investigate age-related neurodegenerative processes. HLA-DR is a major histocompatibility class II cell surface receptor which presents antigens to cells of the immune response. It is a major marker of microglia reaction. In this study, we explored microglia in the whole brains of middle-aged and old microcebes using HLA-DR immunolabeling. We analyzed microglial morphology and quantified HLA-DR+ cell density and protein expression. A wide range of microglial morphologies was observed in the white matter, including thin processes microglia, “rod-like” elongated and polarized shape, hypertrophic, and amoeboid microglia. Aging was associated with increased HLA-DR+ microglial expression in the white matter while very few HLA-DR+ microglia were observed in the parenchyma of cortical gray matter regions. A second finding was the higher number of HLA-DR+ perivascular macrophages in old animals. This study in a primate outlines that, in the absence of neurodegenerative processes, the most prominent signs of age-related microglia/macrophage changes are region-specific and concern white matter and perivascular regions. This emphasizes the need to target these regions to prevent cerebral aging. Main Points: HLA-DR+ microglia in Microcebus murinus primate show diverse morphologies and increase with age in white matter. HLA-DR+ perivascular macrophage load increase in aged animals. Table of Contents Image (TOCI):

  • Open Access

    Intrahippocampal Inoculation of Aβ1–42 Peptide in Rat as a Model of Alzheimer’s Disease Identified MicroRNA-146a-5p as Blood Marker with Anti-Inflammatory Function in Astrocyte Cells

    by Ruth Aquino, Vidian de Concini, Marc Dhenain, Suzanne Lam, David Gosset, Laura Baquedano, Manuel G. Forero, Arnaud Menuet, Patrick Baril, Chantal Pichon

    Circulating microRNAs (miRNAs) have aroused a lot of interest as reliable blood diagnostic biomarkers of Alzheimer’s disease (AD). Here, we investigated the panel of expressed blood miRNAs in response to aggregated Aβ1–42 peptides infused in the hippocampus of adult rats to mimic events of the early onset of non-familial AD disorder. Aβ1–42 peptides in the hippocampus led to cognitive impairments associated with an astrogliosis and downregulation of circulating miRNA-146a-5p, -29a-3p, -29c-3p, -125b-5p, and-191-5p. We established the kinetics of expression of selected miRNAs and found differences with those detected in the APPswe/PS1dE9 transgenic mouse model. Of note, miRNA-146a-5p was exclusively dysregulated in the Aβ-induced AD model. The treatment of primary astrocytes with Aβ1–42 peptides led to miRNA-146a-5p upregulation though the activation of the NF-κB signaling pathway, which in turn downregulated IRAK-1 but not TRAF-6 expression. As a consequence, no induction of IL-1β, IL-6, or TNF-α was detected. Astrocytes treated with a miRNA-146-5p inhibitor rescued IRAK-1 and changed TRAF-6 steady-state levels that correlated with the induction of IL-6, IL-1β, and CXCL1 production, indicating that miRNA-146a-5p operates anti-inflammatory functions through a NF-κB pathway negative feedback loop. Overall, we report a panel of circulating miRNAs that correlated with Aβ1–42 peptides’ presence in the hippocampus and provide mechanistic insights into miRNA-146a-5p biological function in the development of the early stage of sporadic AD.


  • Open Access

    Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice

    by Suzanne Lam, Anne-Sophie Hérard, Susana Boluda, Fanny Petit, Sabiha Eddarkaoui, Karine Cambon, The Brainbank Neuro-Ceb Neuropathology Network, Franck Letournel, Marie-Laure Martin-Négrier, Maxime Faisant, et al.

    Alzheimer's disease (AD) is characterized by intracerebral accumulations of extracellular amyloid-β (Aβ) plaques and intracellular tau pathology that spread in the brain. Three types of tau lesions occur in the form of neuropil threads, neurofibrillary tangles, and neuritic plaques i.e. tau aggregates within neurites surrounding Aβ deposits. The cascade of events linking these lesions and synaptic or memory impairments are still debated. Intracerebral infusion of human AD brain extracts in Aβ plaque-bearing mice that do not overexpress pathological tau proteins induces tau pathologies following heterotopic seeding of mouse tau protein. There is however little information regarding the downstream events including synaptic or cognitive repercussions of tau pathology induction in these models. In the present study, human AD brain extracts (ADbe) and control-brain extracts (Ctrlbe) were infused into the hippocampus of Aβ plaque-bearing APPswe/PS1dE9 mice. Memory, synaptic density, as well as Aβ plaque and tau aggregate loads, microgliosis, astrogliosis at the inoculation site and in connected regions (perirhinal/entorhinal cortex) were evaluated 4 and 8 months post-inoculation. ADbe inoculation produced the following effects: (i) memory deficit; (ii) increased Aβ plaque deposition in proximity to the inoculation site; (iii) tau pathology induction; (iv) appearance of neuropil threads and neurofibrillary tangles next to the inoculation site with a spreading to connected regions. Neuritic plaque pathology was detected in both ADbe- and Ctrlbe-inoculated animals but ADbe inoculation increased the severity close to and at distance of the inoculation site. (v) Finally, ADbe inoculation reduced synaptic density in the vicinity to the inoculation site and in connected regions as the perirhinal/entorhinal cortex. Synaptic impairments were correlated with increased severity of neuritic plaques but not to other tau lesions or Aβ lesions, suggesting that neuritic plaques are a culprit for synaptic loss. Synaptic density was also associated with microglial load. Graphical abstract


  • Open Access

    Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice

    by Suzanne Lam, Anne-Sophie Hérard, Susana Boluda, Fanny Petit, Sabiha Eddarkaoui, Karine Cambon, The Brainbank Neuro-Ceb Neuropathology Network, Jean-Luc Picq, Luc Buée, Charles Duyckaerts, et al.

    Alzheimer’s disease (AD) is characterized by intracerebral accumulations of extracellular amyloid-β (Aβ) plaques and intracellular tau pathology that spread in the brain. Tau lesions occur in the form of neuropil threads, neurofibrillary tangles, and neuritic plaques i.e. tau aggregates within neurites surrounding Aβ deposits. The cascade of events linking these lesions and synaptic or memory impairments are still debated. Intracerebral infusion of human AD brain extracts in Aβ plaque-bearing mice that do not overexpress pathological tau proteins induces tau pathologies following heterotopic seeding of mouse tau protein. There is however little information regarding the downstream events including synaptic or cognitive repercussions of tau pathology induction in these models. In the current study, human AD brain extracts (AD be ) and control-brain extracts (Ctrl be ) were infused in the hippocampus of Aβ plaque-bearing APP swe /PS1 dE9 mice. Memory, synaptic density, as well as Aβ plaque and tau aggregate loads, microgliosis, astrogliosis at the inoculation site and in connected regions (perirhinal/entorhinal cortex) were evaluated 4 and 8 months post-inoculation. AD be inoculation induced memory deficit. It increased deposition of Aβ plaques close to the inoculation site. Tau pathology was also induced in AD be -inoculated mice. Neuropil threads and neurofibrillary tangles occurred next to the inoculation site and spread to connected regions notably the perirhinal/entorhinal cortex. Neuritic plaque pathology was detected in both AD be - and Ctrl be - inoculated animals but AD be inoculation increased the severity close and at distance of the inoculation site. Finally, AD be inoculation reduced synaptic density close to the inoculation site and in connected regions as the perirhinal/entorhinal cortex. Synaptic impairments were correlated with increased severity of neuritic plaques but not of other tau lesions or Aβ lesions, which suggests that neuritic plaques are a culprit for synaptic loss. Synaptic density was also associated with microglial load. Graphical


  • Open Access

    Heterogeneity of Alzheimer’s disease: Insight from a novel mouse model of amyloid and tau lesions based on the inoculation of human brain preparations

    by Suzanne Lam, Susana Boluda, Anne‐Sophie Herard, Fanny Petit, Charles Duyckaerts, Benoit Delatour, Stéphane Haïk, Marc Dhenain

    Background: A major challenge in clinical research is to better understand the heterogeneity of AD. Indeed, AD is heterogeneous regarding its origin, neuropathology and clinical expressions. While classical sporadic forms of AD (clAD) evolve over approximately 10 years, the “rapidly progressive form of AD” (rAD) is a non‐genetic aggressive form associated with a rapid clinical decline that evolves over approximately 2 years (Schmidt et al., Arch Neurol. 2011). Several studies have shown that the experimental inoculation of brain samples with Aβ‐ and/or tau pathology into transgenic (tg) mouse models overexpressing mutant human APP or tau promotes either Aβ or tau aggregation in the brain of the recipient animal (Gary et al., Acta Neuropathol Com. 2019). The phenotype of the inoculated brains is moreover reproduced in the recipient host (Watts et al., PNAS. 2014). The aim of this work was to study the impact of the inoculations of rAD versus clAD‐human brain preparations in tg mice mouse models of β‐amyloidosis to explore the mechanisms associated to AD heterogeneity.Method: Brain samples were characterized pathologically and biochemically. The rAD, clAD, and ctrl (non‐Alzheimer) samples were inoculated in the CA1 region of 2‐month‐old APP/PS1dE9 mice (n = 15‐20/group). At 8 months post‐inoculation, an object recognition task (V‐maze) was conducted to assess memory performance. Aβ deposits (4G8 antibody), tau inclusions (AT8 antibody) and synaptic density were then quantified by immunohistochemistry in the hippocampus.Result: Mice inoculated with either rAD or clAD brain preparations developed a similar increase of Aβ plaques and tau deposits as compared to ctrl‐inoculated mice. However, only the aggressive form of AD (rAD) led to significant cognitive alterations (Figure 1) and synaptic loss (Figure 2) after 8 months.Conclusion: APP/PS1dE9 mice inoculated with AD brain preparations are new models to study both amyloid and tau lesions occurrence. Our results suggest that, independently from the amyloid plaque load or the severity of tau intraneuronal pathology, synaptic health variability may contribute to the heterogeneity of AD‐like phenotype. Acknowledgment: We thank France‐Alzheimer and the NeuroCEB/CNR‐prion brain banks.


  • Open Access

    Encephalopathy induced by Alzheimer brain inoculation in a non-human primate

    by French Neuropathology Network, Charlotte Gary, Suzanne Lam, Anne-Sophie Hérard, James E. Koch, Fanny Petit, Pauline Gipchtein, Stephen J. Sawiak, Raphaëlle Caillierez, Sabiha Eddarkaoui, et al.

    Alzheimer’s disease is characterized by cognitive alterations, cerebral atrophy and neuropathological lesions including neuronal loss, accumulation of misfolded and aggregated β-amyloid peptides (Aβ) and tau proteins. Iatrogenic induction of Aβ is suspected in patients exposed to pituitary-derived hormones, dural grafts, or surgical instruments, presumably contaminated with Aβ. Induction of Aβ and tau lesions has been demonstrated in transgenic mice after contamination with Alzheimer’s disease brain homogenates, with very limited functional consequences. Unlike rodents, primates naturally express Aβ or tau under normal conditions and attempts to transmit Alzheimer pathology to primates have been made for decades. However, none of earlier studies performed any detailed functional assessments. For the first time we demonstrate long term memory and learning impairments in a non-human primate (Microcebus murinus) following intracerebral injections with Alzheimer human brain extracts. Animals inoculated with Alzheimer brain homogenates displayed progressive cognitive impairments (clinical tests assessing cognitive and motor functions), modifications of neuronal activity (detected by electroencephalography), widespread and progressive cerebral atrophy (in vivo MRI assessing cerebral volume loss using automated voxel-based analysis), neuronal loss in the hippocampus and entorhinal cortex (post mortem stereology). They displayed parenchymal and vascular Aβ depositions and tau lesions for some of them, in regions close to the inoculation sites. Although these lesions were sparse, they were never detected in control animals. Tau-positive animals had the lowest performances in a memory task and displayed the greatest neuronal loss. Our study is timely and important as it is the first one to highlight neuronal and clinical dysfunction following inoculation of Alzheimer’s disease brain homogenates in a primate. Clinical signs in a chronic disease such as Alzheimer take a long time to be detectable. Documentation of clinical deterioration and/or dysfunction following intracerebral inoculations with Alzheimer human brain extracts could lead to important new insights about Alzheimer initiation processes.